|
|
|
 |
 |
|
|
Year: 2018 Vol. 22 Num. 2 -
Apr/Junee
DOI: 10.1055/s-0037-1605596
|
Print: |
|
 |
|
|
| The Role of the Level of Interleukin-33 in the Therapeutic Outcomes of Immunotherapy in Patients with Allergic Rhinitis |
|
| How to cite this article |
Nasr WF, Sorour SS, Bahrawy ATE, Boghdadi GS, Shahaway
AAE. The Role of the Level of Interleukin-33 in the Therapeutic Outcomes of Immunotherapy in Patients with Allergic Rhinitis. Int. Arch. Otorhinolaryngol. 2018;22(2):152-156 |
|
| Author(s): |
Wail Fayez Nasr, Samir Sorour Sorour, Atef Taha El Bahrawy, Ghada Samir Boghdadi, Alia A El Shahaway
|
|
|
| Key words: |
| immunotherapy - allergic rhinitis - helper T cells - allergen immunotherapy |
|
|
|
| Abstract: |
Introduction Allergic rhinitis (AR) affects up to 40% of the population and results in nasal itching, congestion, sneezing, and clear rhinorrhea.
Objectives This study aimed to evaluate the changes in the clinical symptoms and in the level of serum interleukin (IL)-33 before and after pollen immunotherapy (IT) in patients with AR.
Methods The total symptom score and the levels of total immunoglobulin E (IgE) and IL-33 were determined in the serum of 10 non-allergic healthy controls and 45 patients with AR who were equally divided into 3 groups: GI (patients did not receive IT), GII (patients had received IT for 6 months) and GIII (patients had received IT for 2 years).
Results There was a significantly higher concentration of IgE and IL-33 in the serum of patients with AR than in that of non-allergic patients. Furthermore, serum level of IL-33 decreased significantly after pollen IT. But, there was no significant reduction in the serum level of IL-33 between GII and GIII patients.
Conclusion Our results show a clinical improvement associated with a decrease in serum level of IL-33 after pollen IT.
|
|
|
|
|
|
|
| |
Print: |
|
|
|
|
|
|
 |
All right reserved. Prohibited the reproduction of papers
without previous authorization of FORL © 1997-
2025
|
 |
|
|
|
PDF in English
Text in English